Navigation Links
iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire/ -- iZumi Bio, Inc., a biotechnology company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells, today announced the appointments of Berta Strulovici, Ph.D., as chief technology officer (CTO) and Dushyant Pathak, Ph.D., as vice president of Business Development.

"The appointments of Drs. Strulovici and Pathak at iZumi are a critical part of our ability to execute on our business strategy as we continue to expand our management team. Berta's deep drug discovery expertise across a wide range of therapeutic areas and technologies, including stem cell technology, will accelerate iZumi's goal of making drug discovery and development faster, more efficient and informed," said John P. Walker, chief executive officer of iZumi. "Dushyant's proven track record in creating alliances with both pharmaceutical partners and research institutions will be instrumental to iZumi's partnering and commercial strategies."

Prior to joining iZumi, Dr. Strulovici served as vice president, Basic Research at Merck Research Laboratories and head of Automated Biology at Merck & Co. At Merck, she was responsible for molecular target identification and led the worldwide development and execution of the early discovery pipeline across all therapeutic areas. Prior to joining Merck in 1996, she held positions at Tularik, Inc. and Syntex Research. Dr. Strulovici received her Ph.D. from the Weizmann Institute of Science in Israel, and conducted her work as a postdoctoral fellow at the Howard Hughes Medical Institute, Duke University Medical Center.

Dr. Pathak joins iZumi from Cellexicon, Inc., where he served as president and chief business officer. He previously held senior management positions at Renovis, Inc., Centaur Pharmaceuticals, and BioProtocol, Inc. Dr. Pathak has more than ten years experience closing strategically important corporate deals resulting in productive alliances with major pharmaceutical partners and research institutions. Dr. Pathak was a Damon Runyon-Walter Winchell Cancer Fund postdoctoral fellow and an associate research scientist at Yale University's Howard Hughes Medical Institute. He completed his doctorate degree at Northwestern University and received his MBA from the Walter A. Haas School of Business at the University of California, Berkeley.

About iZumi Bio

iZumi Bio is a South San Francisco-based biotechnology company initially focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells. Izumi was founded in 2007 and is backed by Kleiner Perkins Caufield and Byers and Highland Capital Partners. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease as well as in cardiovascular disease, where iZumi has a collaboration with The Gladstone Institute of Cardiovascular Disease and Deepak Srivastava, M.D. iZumi is also collaborating with the laboratory of Dr. Shinya Yamanaka of Kyoto University on the research, development and application of iPS technology with the goal of advancing drug discovery and enabling cell-based therapies.

Because iPS cells have stem-cell-like properties and have the potential to differentiate into any cell type, iPS cells are considered to be of great potential for disease research, preclinical drug testing and cell-based therapy. iZumi's approach places the patient at the forefront of the drug discovery process, which could reduce drug development time and increase the probability of success for drug candidates. iZumi plans to use cellular reprogramming, including its iPS technology, to find new molecular targets and develop proprietary therapeutic small molecule or biologic drugs for its own pipeline to treat specific diseases.

SOURCE iZumi Bio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
2. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
3. iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer
4. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
5. Codexis Appoints Singapore Laboratories Managing Director
6. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
10. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):